Home

Flagship Ventures Fund IV-Rx, L.P.

CIK 1590973 · last filed 2022-03-18

Flagship Ventures Fund IV-Rx, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 5 companies since 2016. Across all open-market trades the lifetime net is −$77.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.27B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.27B

Companies

5

Total Filings

9

Lifetime Open-Market Net

-$77.84M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Axcella Health Inc. (AXLA) Delisted 10%+ Owner 81,433 $0.40 $32.6K $172.42M 2 2022-03-18
Evelo Biosciences, Inc. (EVLO) Delisted 10%+ Owner 39,798 $0.00 $4 $33.60M 2 2021-02-04
MRNA 10%+ Owner 21,986,399 $148.87 $3.27B -$313.86M 2 2020-05-26
Rubius Therapeutics, Inc. (RUBY) Delisted 10%+ Owner 5,789,414 $0.08 $480.5K $0 1 2018-07-23
Syros Pharmaceuticals, Inc. (SYRS) Delisted 10%+ Owner 83,866 $0.00 $34 $30.00M 1 2016-07-07

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-12-13 — Notice (144) −55,925 -$12.9K EDGAR
2022-03-18 Axcella Health Inc. (AXLA) Delisted Buy (P) +37,916,226 $72.42M EDGAR
2021-02-04 Evelo Biosciences, Inc. (EVLO) Delisted Buy (P) +1,040,000 $15.60M EDGAR
2020-05-26 MRNA Sell (S) −4,000,000 -$272.88M EDGAR
2019-12-11 MRNA Mixed −48,357,875 -$40.98M EDGAR
2019-05-15 Axcella Health Inc. (AXLA) Delisted Mixed +60,339,740 $100.00M EDGAR
2018-07-23 Rubius Therapeutics, Inc. (RUBY) Delisted Conv (C) +299,668,734 $0 EDGAR
2018-05-15 Evelo Biosciences, Inc. (EVLO) Delisted Mixed +59,613,572 $18.00M EDGAR
2016-07-07 Syros Pharmaceuticals, Inc. (SYRS) Delisted Mixed +27,559,944 $30.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.